Sas version 11

As this trial was an exploratory study to evaluate the utility of continuous adjuvant UFT therapy in patients previously treated with NAC and there are currently no data from previous studies evaluating the tolerability of adjuvant UFT as a primary endpoint, we did not calculate a formal sample size using statistical data from previous comparable studies. Moreover, we considered that a number of cases were required for further exploratory analyses. Consequently, accrual of 50 patients was planned for this study. DFS was calculated using the Kaplan-Meier method. Statistical analyses were performed using SAS version 11.0 (SAS Institute, Cary, NC, USA). most frequent grade 3 AEs that were observed in 7% and 3% of patients, respectively. Grade 3 leucopenia and neutropenia were both observed in 3% of patients. We observed important common non-hematological toxicities of various grades, including anorexia, stomatitis, dysgeusia, rash, and skin hyperpigmentation. No grade 3 or greater non-hematological AEs or unexpected serious AEs were observed in this study.

Odds ratios (ORs) and 95% confidence intervals (95% CIs) are provided. Differences of age and BMI between men and women were examined by non-paired t-test. Differences in age, height, weight, and BMI among the urban, mountainous, and coastal communities were determined using one-way analysis of covariance and Tukey's honestly significant difference test. We used the chi square test to compare the prevalence of radiographic hip OA between men and women. Association of prevalence with age was determined by logistic-regression analysis after adjustment for BMI. Association of the variables such as age, BMI, gender, and community with radiographic hip OA was evaluated by multivariate logistic-regression analysis. Logistic-regression analyses were used to estimate OR and the associated 95% CI of K/L ¼ 2 and K/L ! 3 hip OA for pain compared with K/L ¼ 0/1 after adjustment for age, BMI, and community. Data analyses were performed using SAS version 11.0 (SAS Institute Inc., Cary, NC).